Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.

Publication Title

Cancer Immunol Res

Document Type

Article

Publication Date

4-1-2019

Abstract

Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the identification and characterization in one patient of T-cell receptors (TCRs) recognizing mutated p53 p.R175H, which is shared among a subset of patients with cancer. Tumor-infiltrating lymphocytes were screened for recognition of mutated neoantigens in a patient with metastatic colorectal cancer. HLA-A*0201-restricted recognition of mutated p53 p.R175H was identified, and the minimal peptide epitope was HMTEVVR

Clinical Institute

Cancer

Clinical Institute

Digestive Health

Specialty/Research Institute

Earle A. Chiles Research Institute

Specialty/Research Institute

Oncology

Specialty/Research Institute

Gastroenterology

Share

COinS